Search

Displaying results 2961 - 2970 of 10000 in total
  1. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … fragment C5a and its cognate C5aR receptor in AAV.

  2. Drug

    Nitrous oxide

    go.drugbank.com/drugs/DB06690
    ApprovedInvestigationalVet approved

    It is used in surgery and dentistry for its anesthetic and analgesic effects. … It is known as "laughing gas" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug.

    Mixtures: Nitrous Oxide In OxygenProducts: N/A, Nitrous Oxide 100%
  3. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … The approved application holder removed Merital capsules from the market on January 23, 1986.

  4. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite. … [L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143]

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Acetyldigitoxin

    go.drugbank.com/drugs/DB00511
    Approved

    Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Influenza A virus A/Singapore/INFIMH-16-0019/2016 IVR-186 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14587
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25ml
  7. Drug

    EA-230

    go.drugbank.com/drugs/DB19114
    Investigational

    EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).

  8. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. … [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296]

  9. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … involved in organ regeneration and tissue repair.

  10. Drug

    Potassium guaiacolsulfonate

    go.drugbank.com/drugs/DB13735
    ApprovedWithdrawn

    Guaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.

    Mixtures: ARTU 100 ML SURUP, ANTIBEKSIN SURUP, 100 ML